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In contrast to the prevalence of oesophageal squamous cell carci-
noma (SCC), that of oesophageal adenocarcinoma is rapidly
increasing in Western countries. Oesophageal adenocarcinoma is
thought to arise from metaplastic mucosa of intestinal-type located
in the distal part of oesophagus above the lower oesophageal
sphincter, a condition also known as Barrett’s oesophagus (BE)
(Jankowski et al, 1999). Replacement of normal squamous mucosa
by Barrett’s intestinal-type mucosa is believed to result from injury
caused by gastric and duodenal contents regurgitating to oesoph-
agus (Jankowski et al, 1999). The presence of specialized columnar
epithelium of intestinal type is associated with increased risk of
dysplastic changes and malignant transformation. Progression of
BE to dysplasia and carcinoma is usually being followed by
oesophagogastroscopies and biopsies but there are no reliable para-
meters to evaluate each patient’s risk of developing oesophageal
adenocarcinoma. The prognosis of Barrett’s carcinoma is poor; 5-
year survival is less than 15% (Antonioli and Wang, 1997), but if
diagnosed and surgically treated early, Barrett’s carcinoma is
potentially curable (Peters et al, 1994). Despite intensive research,
molecular events which take place during progression of normal
squamous mucosa to Barrett’s oesophagus and further to dysplasia
and adenocarcinoma are not fully understood. 
Matrix metalloproteinases (MMPs) are a group of Ca2+-
dependent, zinc-containing enzymes which are altogether able to
degrade all components of extracellular matrix (ECM) (Nagase and
Woessner, 1999). MMPs participate in physiological processes like
tissue morphogenesis, wound repair, and angiogenesis as well as in
pathologic conditions such as arthritis, inflammatory bowel
disease, atherosclerosis, and tumour growth and metastasis
(Kahari and Saarialho-Kere, 1999). MMPs have been implicated
in all aspects of tumour progression; they enhance tumour-induced
angiogenesis, destroy local tissue architecture to allow tumour
growth, and break down basement membranes in the process of
metastatic spread. Different MMPs are often co-expressed in
cancers in a cell-type specific manner and, thus, complement the
proteolytic capacity of each other. The MMP family currently
comprises 21 structurally related members which can be divided
into collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and 
-9), stromelysins (MMP-3, -7, -10, -11, -12), membrane-type
MMPs (MMP-14, -15, -16 and -17) and other MMPs (MMP-19,
-20, -23 and -26) according to their structure and substrate speci-
ficity (Nagase and Woessner, 1999; Velasco et al, 1999; Park et al,
2000). MMPs not only degrade ECM components but they also
modulate cell migration (Koshikawa et al, 2000) as well as
immunologic response e.g. by shedding FasL (Tanaka et al, 1998)
and they activate certain cytokines such as TNF-a and IGF
(Chambers and Matrisian, 1997). 
Collagenases are the principal proteinases that degrade native
fibrillar collagens. Substrates of collagenase-1 include collagens I,
II, III, VII, VIII and X, gelatin, aggrecan, versican, entactin,
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http://www.bjcancer.comtenascin and proteoglycan link protein (Kahari and Saarialho-
Kere, 1999). Collagenase-1 has been associated with poor prog-
nosis in oesophageal cancers (Murray et al, 1998). Collagenase-3
has a broader substrate specificity being capable of degrading
collagens I, II, III, IV, IX, X and XIV, gelatin, tenascin, fibronectin
and laminin-1 (Kahari and Saarialho-Kere, 1999). 
Stromelysin-2 (MMP-10) degrades in vitro e.g. collagen III and
IV, gelatin, aggrecan, elastin, and proteoglycan core proteins
(Murphy et al, 1991; Chandler et al, 1996). Expression of
stromelysin-2 has been associated with invasion of epithelial
cancers (Kerkela et al, 2001). Matrilysin is the smallest MMP and
its in vitro substrates include proteoglycans, aggrecan, gelatin,
fibronectin, tenascin and elastin as well as BM components
nidogen, laminin and type IV collagen (Murphy et al, 1991).
Matrilysin expression has been associated with epithelial tumours
of the colon, prostate and breast (Fingleton et al, 1999).
Furthermore, transfection of matrilysin cDNA enhances the inva-
sive potential of colon cancer cells (Adachi et al, 1999). Human
macrophage metalloelastase (MMP-12) is the most elastolytic
MMP, but it also degrades type IV collagen, laminin-1,
fibronectin, vitronectin, proteglycans and, like matrilysin, it
cleaves plasmin to angiostatin (Chandler et al, 1996; Gronski et al,
1997). 
The activity of MMPs is regulated at the transcriptional level by
cytokines and growth factors and after secretion by proenzyme
activation or by their natural tissue inhibitors, TIMPs-1, -2, -3 and
-4, which inhibit MMPs by binding covalently to the active site of
the enzyme. TIMP-1 is a very potent inhibitor of MMPs except
MT-MMPs. TIMP-3 inhibits the activity of MMPs-1, -2, -3, -9 and
-13 (Apte et al, 1996) but also the activity of MT-MMPs as well as
TNF-a converting enzyme (TACE). However, the role of TIMPs
is not restricted to the inhibition of MMPs. They possess growth
promoting activities for various cell types as well and have antian-
giogenic properties and promote apoptosis (Martin et al, 1996;
Anand-Apte et al, 1997; Ahonen et al, 1998). 
In this work the expression patterns of collagenase-1 (MMP-1)
and -3 (MMP-13), stromelysin-2 (MMP-10), metalloelastase
(MMP-12), matrilysin (MMP-7) and their tissue inhibitors, TIMP-
1 and -3, were investigated in Barrett’s oesophagus and adenocar-
cinoma. Furthermore, since the expression of tenascin-C and
laminin-5 in tumors has been shown to correlate with high risk of
invasiveness in certain cancer types (Pyke et al, 1995; Jahkola et
al, 1996), their expression was also investigated. Our results
demonstrate that matrilysin and metalloelastase are already upreg-
ulated in intestinal metaplasia and that TIMPs-1 and -3 are differ-
entially regulated during transformation. 
MATERIALS AND METHODS 
Tissue samples 
Patients were followed for Barrett’s intestinal metaplasia, 
diagnosed by an experienced pathologist, or surgically treated 
for Barrett’s oesophageal adenocarcinoma in Helsinki University
Central Hospital, Finland. Formalin-fixed, paraffin-embedded spec-
imens of Barrett’s oesophageal adenocarcinoma (n = 16, 6 with
lymph node metastasis) and intestinal metaplasia (n = 5) were
obtained from the Department of Pathology, University of
Helsinki. 8 of the samples were biopsies taken during 
upper gastrointestinal endoscopy and 13 were surgical speci-
mens. In situ hybridizations for matrilysin and metalloelastase
were performed also on additional biopsy specimens (n = 10)
taken during follow-up of 10 patients, which later devel-
oped matrilysin-positive Barrett’s carcinoma. 4 samples only
contained intestinal metaplasia, while 6 of them were follow-
up biopsies in which the later operated cancer was initially diag-
nosed. 6 samples of normal oesophageal mucosa (n = 6) were also
examined. 
Definition used for BE was presence of specialized intestinal-
type columnar epithelium with mixed population of goblet, Paneth
and endocrine cells lining a segment of distal oesophagus above
the lower oesophageal sphincter. TNM-classification for each
tumour was based on findings during operation and on patholo-
gist’s analysis. Preoperative CT-scan and abdominal ultrasound
investigations were performed in all cases. 
In situ hybridization 
The production and specificity of the anti-sense collagenase-1,
collagenase-3, metalloelastase, matrilysin, stromelysin-2, as well
as TIMP-1 and -3 probes have previously been described
(Saarialho-Kere et al, 1994, 1996; Vaalamo et al, 1996, 1997,
1998; Airola et al, 1998). In situ hybridization was performed 
on 4-mm sections. Following deparaffinization and rehydration 
all samples were treated with proteinase K and were washed 
in 0.1 mol l–1 triethanolamine buffer containing 0.25% acetic 
anhydride. Sections were hybridized overnight at 50˚C to 55˚C
with  35S-labelled RNA probe. After hybridization, slides 
were washed under stringent conditions and treated with RNAse 
A to remove unhybridized probe. After 20 to 40 days autoradio-
graphic exposure, the photographic emulsion was developed 
and the slides were stained with haematoxylin and eosin.
Previously positive samples for each anti-sense probe were used 
as positive controls (colon cancers for TIMP-3, sweat 
gland tumours for matrilysin, chronic wounds for TIMP-1, colla-
genase-1 and stromelysin-2, squamous cell carcinomas for 
collagenase-3, and sarcoid granulomas for metalloelastase). The
slides were independently assessed by two experienced investiga-
tors (U S-K, M-L K-L). 
Immunohistochemistry 
Macrophages were stained using a monoclonal antibody (KP-1,
Dako Corp, Carpinteria, CA, product M814), which reacts with
CD68, a specific macrophage marker. The cells producing
laminin-5 were detected with polyclonal antibodies against the g-2
chain of laminin-5, provided by Prof Karl Tryggvason, Karolinska
Institut, Stockholm, Sweden (Pyke et al, 1994). The extracellular
matrix component tenascin-C was stained by using mouse mono-
clonal antibodies (no. 1927, Chemicon, Temecula, CA). 
Anti-CD68 antibody was diluted 1:400, laminin-5 1:500 and
tenascin 1:2000. CD68 and tenascin antibodies reacted for 1 h at
37˚C and antibody for laminin-5 reacted overnight at 4˚C.
Immunohistochemistry was performed using the avidin–biotin–
peroxidase complex technique (Saarialho-Kere et al, 1992).
Sections were pretreated with 10 mg ml–1 trypsin. Diaminobenzi-
dine (DAB) was used as chromogenic substrate and sections 
were counterstained with Harris haematoxylin. Controls were
performed with rabbit pre-immune serum or normal mouse
immunoglobulins. 
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Table 1 TNM classification and tumour grading for each sample 
Gender Age TNM Survival Differentiation MMP-1 MMP-13 MMP-7 MMP-10 MMP-12 TIMP-1 TIMP-3 Tenascin Laminin-5 
F 67 IM, no dysplasia N.D. – N.D. – N.D. – + – – 
M 50 IM, no dysplasia + – + – + + ++ – – 
F 53 IM, no dysplasia – – + – (+) + + – – 
M 68 IM, no dysplasia – – – (+) ++ – + – – 
M 70 IM, no dysplasia – – – – – – – – – 
M 48 IM, mild dysplasia – (+) – – + (+) ++ – – 
M 73 T3N1M0 with M N.D. poor ++ + +++ – + + + + +++ 
M 52 T3N0M0 27 † poor ++ – +++ – ++ +++ – (+) + 
M 57 T3N1M0 4 † poor – – +++ N.D. +++ – +++ +++ ++ 
T3N1M0 with M 4 † poor + + + – – + – + ++ 
T3N1M0 4 † high + + + – ++ – +++ (+) (+) 
M 53 T3N1M0 with M 24 poor/high + + +++ + +++ ++ ++ +++ ++ 
T3N1M0 with M 24 poor/high + – +++ + ++ (+) ++ +++ ++ 
M 63 T3N1M0 with M 18 poor/high +++ (+) + + +++ ++ +++ + + 
M 69 T2N0M0 24 high – – + – + ++ ++ (+) – 
M 78 T2N1M0 30 † high – – – – – – – – – 
M 63 T2N0M0 16 high – – + – + – + + – 
M 52 T4N0M0 37 high (+) – ++ – ++ ++ ++ + ++ 
M 77 T3N1M1 N.D. high + – + – – ++ +++ (+) – 
T3N1M1 with M N.D. high + – – – (+) + ++ – (+) 
M 64 T2N0M0 2 † high ++ – +++ – + ++ ++ + ++ 
M 70 T1N1M0 23 high + + + – – (+) ++ + (+) 
M 50 T3N1M0 with M 5 high – – ++ – ++ ++ ++ ++ ++ 
M 81 TxNxM0 14 high – – – – + – – + – 
F 82 TxN0M0 24 high – – – + + + – (+) – 
Tumours positive for each probe or antibody used 9/15 4/15 12/15 3/15 13/15 12/15 11/15 14/15 10/15 
N.D., not determined; –, no signal detected; (+), signal in occasional cells; +, specific signal in low number of cells; ++, specific signal in moderate number of cells; +++, specific signal in high number of cells; IM,
intestinal metaplasia; M, metastasis. Survival time is stated in months. RESULTS 
Matrilysin is expressed by malignant cells in Barrett’s
carcinoma and is up-regulated early in oncogenesis 
Matrilysin mRNA was detected in 12/15 samples of Barrett’s carci-
noma. Most abundant expression was detected in poorly differenti-
ated tumours (Table 1; Figure 1A). Matrilysin was expressed
throughout the tumour, not only at the invasive border (Figure 1A). 
mRNA for matrilysin was seen already in samples of intestinal
metaplasia (Table 1; Figure 2A,B) suggesting that it is upregulated
early in oncogenesis. Furthermore, in situ hybridization on follow-
up biopsies showed matrilysin expression in 3/6 biopsies with
adenocarcinoma and in 2/4 biopsies with intestinal metaplasia
(data not shown). All 10 patients followed by biopsies later devel-
oped matrilysin-positive adenocarcinoma of oesophagus. 
Positive signal for matrilysin was seen in 4/6 lymph nodes with
metastatic tissue (Figure 2C). Primary tumours from which metas-
tases originated were also highly positive for matrilysin mRNA. No
signal for matrilysin mRNA was detected in normal oesophagus.
Tenascin-C protein was produced bordering or inside areas abun-
dant with matrilysin mRNA positive cells (Figures 1A, F, 2D, E). 
Collagenase-1 is expressed by malignant cells, but
stromelysin-2 and collagenase-3 are rarely detected in
Barrett’s carcinoma 
Collagenase-1 mRNA was seen in 9/15 tumours. Carcinoma cells
(Figure 2F,G), as well as stromal fibroblast-like cells (data not
shown) expressed collagenase-1. No signal for collagenase-1
mRNA was seen in lymph node metastases or in samples with
plain intestinal metaplasia (Table 1). 
Signal for stromelysin-2 and collagenase-3 were detected only
in 3/15 and 4/15 tumours, respectively, and never in metastases
(Table 1). Expression of stromelysin-2 was seen in luminal surface
area of tumours, not in the invasive border (data not shown).
Collagenase-3 was detected in occasional fibroblast-like cells of
the stroma (data not shown). Signal for stromelysin-2 or collage-
nase-3 mRNAs was not detected in intestinal metaplasia (Table 1). 
Metalloelastase is expressed by a subset of
macrophages 
MMP-12 mRNA was detected in 13/15 tumours. Particularly,
well-differentiated tumour regions had lots of infiltrating MMP-
12 -positive cells (Figure 1B; 3A,B). As assessed with immuno-
staining for CD68 (Figure 3C,D), MMP-12 was produced by a
subset of macrophages. Signal for MMP-12 mRNA was seen also
in 3/6 lymph node metastases (Figure 3E). MMP-12 expression
was detected also in 4/6 samples of intestinal metaplasia (Figure
3F,G) but the number of positive cells was greater in cancer 
(Table 1). Follow-up biopsies showed expression of MMP-12 in
3/6 biopsies with adenocarcinoma and in 2/4 biopsies with
intestinal metaplasia (data not shown). 
TIMP-1 and -3 are expressed by fibroblast-like cells
within the tumour 
TIMP-1 expression was detected in 12/15 tumours (Figures 1C,
4A). It was not expressed in the surface of tumours, but 
abundantly in deeper areas of the mucosa, particularly, in aggres-
sive tumours with poor histological differentiation (Figure 1C).
TIMP-1 was detected in stromal cells surrounding glandular struc-
tures in 4/6 lymph-node metastases (Figure 4H). Occasional signal
for TIMP-1 was observed in stromal cells between glands in 3/6
intestinal metaplasia samples, in which the degree of expression
was very low compared to malignant samples (data not shown,
Table 1). 
Signal for TIMP-3 mRNA was detected in 11/15 tumours
(Figures 1D, 4C). Cells expressing TIMP-3 were stromal, fibro-
blast-like cells (Figure 4D). In poorly differentiated tumours,
TIMP-3 was expressed by stromal cells throughout the malignant
tissue, whereas in tumours with high differentiation, cells positive
for TIMP-3 mRNA lined the malignant cell islands (Figure 1D).
Expression of TIMP-3 was detected in 5/6 samples of intestinal
metaplasia (Figure 4F, G) and in 5/6 lymph node metastases
(Figure 4I). 
Protein expression of tenascin-C and laminin-5 is most
prominent in poorly differentiated tumours 
Tenascin-C immunoreactivity was detected in 14/15 tumours, but
no staining was seen in samples of intestinal metaplasia.
Expression was abundant particularly in poorly differentiated
tumours (Figure 1F), where it seemed to form net-like structures
between invasive cells, which were positive for laminin-5 and
matrilysin mRNA (Figure 1A, E). 
Positive laminin-5 staining was detected in tumour cells partic-
ularly at the invasive front (Figure 1E). Matrilysin mRNA and
laminin-5 protein partly colocalized (Figure 1A, E). No staining
for laminin-5 was seen in intestinal metaplasia (data not shown). 
DISCUSSION 
Compared to the normal population, patients with Barrett’s
oesophagus have up to 125-fold increased risk for developing
oesophageal adenocarcinoma (Bonelli 1993). Patients followed
endoscopically have better prognosis than other patients who
develop oesophageal adenocarcinoma (Peters et al, 1994; van
Sandick et al, 1998). During endoscopic examination several biop-
sies are taken, but the risk of missing the exact dysplastic or malig-
nant tissue is still present. Furthermore, lack of reliable parameters
to evaluate each BE patient’s risk of developing invasive tumour,
has encouraged to search new markers to help the evaluation. 
In situ hybridization is a useful method for studying expression
of MMPs, because transcriptional regulation is an important
pathway for MMP induction (Westermarck and Kahari, 1999).
Instead of storing enzymes in cytoplasmic structures, MMPs and
TIMPs studied in this work are secreted readily to the extracellular
space. Only one previous study on MMPs in oesophageal adeno-
carcinoma exists. By immunohistochemistry Murray et al (1998)
found that MMP-1, MMP-2 and MMP-9 are expressed in 30%,
81% and 78% of oesophageal adenocarcinomas, respectively.
They also found that expression of MMP-1 correlates with poor
prognosis in oesophageal cancers. Furthermore, Shima et al (1992)
found that in oesophageal SCC, expression of 72-kDa gelatinase
(MMP-2) and stromelysin-1 (MMP-3) is associated with lymph-
node metastasis and vascular invasion. 
Matrilysin was abundantly expressed in our material, particu-
larly in poorly differentiated tumours which had strong
immunostaining for laminin-5 at the invasive border. Matrilysin
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in which its expression correlates with poor prognosis
(Yamamoto et al, 1999). While this study was in progress
Yamashita et al (2000) showed by Northern hybridization and
Ohashi et al (2000) by immunohistochemistry that matrilysin
expression status might be a prognostic factor in patients with
oesophageal squamous cell carcinoma. Laminin-5 is often
considered as a marker for invasiveness (Skyldberg et al, 1991;
Pyke et al, 1995) since invading malignant cells express and
adhere to laminin-5 (Pyke et al, 1994) and migrate on it (Tani et
al, 1997). The role of matrilysin in Barrett’s carcinoma is most
likely the same as in gastric and colon cancers. Matrilysin
increases the invasive potential of malignant colon cancer cells
(Adachi et al, 1999), but is also required for tumour initiation and
growth (Fingleton et al, 1999). In addition to its degradative
effects on ECM, matrilysin also activates proMMP-2, which is
known to be produced in 81% of oesophageal adenocarcinomas
(Murray et al, 1998). 
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Figure 1 Expression patterns of MMPs-7 and -12, TIMPs-1 and -3 and laminin-5 as well as tenascin in Barrett’s cancer. (A) Matrilysin expression by
carcinoma cells in a poorly differentiated tumour. Well-differentiated area on the right side shows much lower matrilysin expression. (B) MMP-12 mRNA is
produced by stromal cells surrounding neoplastic glands in the well-differentiated part of the same tumour. In the aggressive area of tumour, MMP-12
expression is nearly absent. (C) TIMP-1 is expressed particularly in the poorly differentiated area. (D) Expression of TIMP-3 is abundant in poorly differentiated
as well as well-differentiated areas. (E) Laminin-5 is produced by invading tumour cells implicating their migratory status. Production of laminin-5 partly
colocalizes with that of matrilysin (A). (F) Tenascin-C is produced at the poorly differentiated area of the tumour particularly at the invasive border. Arrows depict
corresponding spots. Magnification x20 (A–F) As in preinvasive lesions of colorectal carcinoma, adenoma and
carcinoma in situ (Fingleton et al, 1999), we found matrilysin
expression in premalignant lesions of the oesophagus. This suggests
that metaplasia-dysplasia-adenocarcinoma sequence in oesophagus
has some features in common with colorectal adenoma-carcinoma
sequence and that matrilysin might be significant also in develop-
ment of BE and oesophageal adenocarcinoma. Another feature in
common with colorectal cancer is APC-gene mutations (Mueller et
al, 2000), which lead to accumulation of beta-catenin. Together
with the DNA-binding protein TCF-4, b-catenin functions as a tran-
scriptional activator for matrilysin (Brabletz et al, 1999). 
Tenascin-C is a large glycoprotein of the extracellular matrix
with growth-promoting and anti-adhesive functions. Tenascin-C
has previously been demonstrated to be involved in carcinogenesis
in other types of cancer (Jahkola et al, 1996). Interestingly, our
novel results show that tenascin-C is produced particularly in
aggressive and poorly differentiated oesophageal adenocarci-
nomas, but not in intestinal metaplasia. Cells in these areas also
stained with laminin-5, which implicates migrating status of
malignant cells in contact with tenascin-C protein. Tenascin-C
may help invading cells detach from surrounding matrix and cells.
Of the MMPs, only matrilysin was systematically expressed in the
same regions as tenascin-C. Matrilysin is known to degrade both
large and small tenascin-C isoforms, and large isoform is cleaved
also by MMP-2 and MMP-3 (Siri et al, 1995). Tenascin is also
degraded by MMP-1 and MMP-13, but neither of them was
388 MT Salmela et al 
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Figure 2 Matrilysin and collagenase-1 expression in Barrett’s carcinoma. (A) Matrilysin expression in intestinal metaplasia by epithelial cells. 
(B) Corresponding bright-field image. (C) Bright-field image of a lymph node metastasis with matrilysin expressing cells. (D) Tenascin-C positive area is in
immediate contact with matrilysin expressing tumour cells. (E) Expression of matrilysin in another poorly differentiated tumour. (F) Collagenase-1 expression in
a poorly differentiated tumour in the invading carcinoma cells. (G) Corresponding higher magnification bright-field image. Arrows depict corresponding spots
(D, E). Magnification x20 (D, E), x40 (A, B) x100 (F) and x200 (C, G) 
A
C D E
G F
Bexpressed in areas positive for tenascin. Therefore tenascin-C
could well be degraded by matrilysin during invasion and cell
migration processes. At least in early breast cancer, tenascin-C
expression in the invasion border is a strong predictor of distant
metastasis (Jahkola et al, 1996). In addition to matrilysin, also
tenascin-C might be a useful marker when progression of BE to
adenocarcinoma is evaluated. 
We detected stromelysin-2 expression only in few tumours with
positive cells located at tumour surface and not in the invasive
front. Upregulation of stromelysin-2 has not been detected in
gastric, colon and breast adenocarcinomas (McDonnell et al, 1991;
Heppner et al, 1996), but it is overexpressed in SCCs of the head
and neck (Kerkela et al, 2001). Our results support the hypothesis,
that stromelysin-2 expression is limited to epithelial SCCs and not
associated with malignant transformation of adenocarcinomas.
Stromelysin-2 expression in our samples is probably related to the
inflammatory reaction and wound healing-type processes at the
luminal surface of tumours. 
Surprisingly, signal for collagenase-3 was detected only occa-
sionally in oesophageal adenocarcinomas, although it seems to be
Metalloproteinases in Barrett’s adenocarcinoma 389
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Figure 3 MMP-12 is expressed by macrophages. (A) MMP-12 expression in a well-differentiated area of the tumour shown in Figure 1. (B) Corresponding
bright-field image. (C) MMP-12 is expressed by a subset of macrophages as assessed with immunostaining for macrophage marker CD68 (D). Arrows depict
corresponding spots. (E) Lymph node metastasis with MMP-12 expressing cells surrounding metastatic glands. (F) MMP-12 expression in oesophageal mucosa
exhibiting intestinal metaplasia. (G) High magnification on cells expressing MMP-12 beneath the metaplastic epithelium. Magnification x40 (E), x100 (A, B, F),
x200 (C, D), and x400 (G). 390 MT Salmela et al 
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Figure 4 Expression of TIMPs-1 and -3 by stromal cells in Barrett’s carcinoma. (A) TIMP-1 expression by activated fibroblast/macrophage-like cells in well-
differentiated tumour. (B) High magnification on TIMP-1 positive cells. (C) TIMP-3 expression in serial section. (D) High magnification on TIMP-3 positive
activated fibroblast/macrophage-like cells. (E) Bright-field image corresponding to picture C. (F) TIMP-3 is expressed by stromal cells also in intestinal
metaplasia. (G) Corresponding bright-field image. (H) TIMP-1 is abundantly expressed in a metastatic lymph node. (I) Also TIMP-3 is expressed in a great
number of cells in a metastastatic lymph node. Magnification x100 (A, C, E–I), and x400 (B, D). 
A
C
B
D
E F G
H Ispecifically upregulated in SCCs of the head and neck (Johansson
et al, 1997), larynx (Cazorla et al, 1998) and vulva (Johansson 
et al, 1999). While this study was in progress, Etoh et al (2000)
demonstrated that in oesophageal SCCs production of MMP-13 is
implicated in tumour aggressiveness and prognosis. Thus,
collagenase-3 could be a specific marker for transformation of
squamous epithelium. In contrast to low production of collage-
nase-3, we detected collagenase-1 expression in 9/15 tumours and
its production was associated with poor differentiation. Cells posi-
tive for MMP-1 mRNA were malignant as well as stromal cells.
As most MMPs, collagenase-1 is expressed only by stromal cells
in colonic and gastric carcinomas, but in oesophageal SCCs also
malignant cells produce MMP-1 (Murray et al, 1998). 
MMP-12 was expressed by a subset of macrophages as assessed
by immunostaining for the macrophage marker CD68.
Interestingly, it was more abundantly expressed in well than
poorly differentiated tumours. MMP-12 cleaves, at least in vitro,
plasminogen to angiostatin which induces apoptosis in endothelial
cells (Lucas et al, 1998) and may in this way inhibit angiogenesis.
Expression of MMP-12 could reflect host-response to tumour
tissue. MMP-12 is induced in monocyte/macrophages by
macrophage contact with T cells. Furthermore, several cytokines
upregulated in cancers, such as IL-1b, TNF-a, VEGF and GM-
CSF, can upregulate MMP-12 secretion by peripheral-blood-
derived macrophages (Feinberg et al, 2000). 
In addition to MMP-12, also TIMP-1 and -3 have antiangio-
genic properties. Like in well-differentiated cutaneous and oral
SCCs (Sutinen et al, 1998; Airola et al, 1999), both of these MMP
inhibitors were abundantly expressed by stromal fibroblast-like
cells. In contrast to TIMP-1, which was expressed in deeper areas
of lesions, TIMP-3 was expressed throughout the cancer tissue,
and in larger numbers of cells. These observations might reflect
different biological roles of these two TIMPs; TIMP-1 is up-
regulated after malignant cells protrude into muscle layer and
deeper parts of mucosa, whereas TIMP-3 is up-regulated earlier in
oncogenesis. The present results further substantiate previous data
on a positive correlation between elevated TIMP levels and higher
invasiveness (Airola et al, 1999). 
In conclusion, our results provide evidence that matrilysin is the
principal MMP expressed by malignant cells in Barrett’s adenocar-
cinoma. Furthermore, in our material 4/6 lymph-node metastases
and the primary tumours from which they were originated showed
matrilysin expression, strongly suggesting a crucial role for
matrilysin in invasion and metastasis of Barrett’s adenocarcinoma.
We also concluded that matrilysin and tenascin-C might be useful
markers for evaluating progression of BE to adenocarcinoma. 
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